CEO Zook exits Vivus, J&J's Fischer steps in
This article was originally published in Scrip
Executive Summary
Vivus' freshly appointed CEO, Tony Zook who joined the Mountain View, California-based firm from big pharma AstraZeneca, has stepped down due to "a previously-diagnosed medical condition." Taking up the position instead is Seth H Z Fischer, former Johnson and Johnson company group, and worldwide franchise chair – effective 3 September 2013. Mr Fischer will also join the Vivus board of directors.
You may also be interested in...
Orexigen Follows Through On Warning It May Have To Liquidate
Orexigen hoped its go-it-alone strategy would boost obesity drug Contrave's sales enough to keep the company afloat, but now it has initiated bankruptcy proceedings, following through on a warning in October that it might not meet debt holders' requirements.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.